DK1499736T3 - Forbedrede kimære glycoproteiner og pseudotypet lentovirale vektorer - Google Patents
Forbedrede kimære glycoproteiner og pseudotypet lentovirale vektorerInfo
- Publication number
- DK1499736T3 DK1499736T3 DK03747185T DK03747185T DK1499736T3 DK 1499736 T3 DK1499736 T3 DK 1499736T3 DK 03747185 T DK03747185 T DK 03747185T DK 03747185 T DK03747185 T DK 03747185T DK 1499736 T3 DK1499736 T3 DK 1499736T3
- Authority
- DK
- Denmark
- Prior art keywords
- vectors
- pseudotyped
- medium
- lentoviral
- producer cell
- Prior art date
Links
- 239000013598 vector Substances 0.000 title abstract 4
- 102000003886 Glycoproteins Human genes 0.000 title abstract 3
- 108090000288 Glycoproteins Proteins 0.000 title abstract 3
- 239000002245 particle Substances 0.000 abstract 2
- 239000013603 viral vector Substances 0.000 abstract 2
- 238000012258 culturing Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15045—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37565402P | 2002-04-26 | 2002-04-26 | |
PCT/IB2003/001597 WO2003091442A1 (en) | 2002-04-26 | 2003-04-25 | Improved chimeric glycoproteins and pseudotyped lentiviral vectors |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1499736T3 true DK1499736T3 (da) | 2009-06-08 |
Family
ID=29270681
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK03747185T DK1499736T3 (da) | 2002-04-26 | 2003-04-25 | Forbedrede kimære glycoproteiner og pseudotypet lentovirale vektorer |
Country Status (13)
Country | Link |
---|---|
US (2) | US8338168B2 (zh) |
EP (1) | EP1499736B1 (zh) |
JP (1) | JP4343708B2 (zh) |
KR (1) | KR101002955B1 (zh) |
CN (1) | CN100340668C (zh) |
AT (1) | ATE424464T1 (zh) |
AU (1) | AU2003226598A1 (zh) |
CA (1) | CA2484166C (zh) |
DE (1) | DE60326444D1 (zh) |
DK (1) | DK1499736T3 (zh) |
ES (1) | ES2326217T3 (zh) |
HK (1) | HK1073479A1 (zh) |
WO (1) | WO2003091442A1 (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2019144A1 (en) * | 2007-07-23 | 2009-01-28 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Vector particles for targeting CD34+ cells |
KR101790187B1 (ko) * | 2009-07-24 | 2017-10-25 | 이뮨 디자인 코포레이션 | 신드비스 바이러스 외피 당단백질로 가성형태화된 렌티바이러스 벡터 |
US9839684B2 (en) | 2011-04-06 | 2017-12-12 | Biovaxim Limited | Pharmaceutical compositions comprising inactivated HIV viral particles and non-pathogenic lactobacilli for the induction of antigen-specific immunotolerance |
WO2013045639A1 (en) | 2011-09-29 | 2013-04-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | LENTIVIRAL VECTORS PSEUDOTYPED WITH MUTANT BaEV GLYCOPROTEINS |
ES2717876T3 (es) | 2011-12-12 | 2019-06-26 | Childrens Hospital Philadelphia | Sistema de producción de un vector lentiviral a gran escala comercial y vectores así producidos |
WO2014018850A2 (en) * | 2012-07-27 | 2014-01-30 | The Trustees Of The University Of Pennsylvania | Cytoplasmic tail modifications to boost surface expression and immunogenicity of envelope glycoproteins |
CN106029873A (zh) * | 2013-12-24 | 2016-10-12 | 埃姆医疗有限公司 | 离体的抗体生产 |
EP3194602B1 (en) * | 2014-09-18 | 2019-11-06 | Université de Montréal | Compounds and methods for enhancing viral gene transfer to human hematopoietic cells |
CA3141018A1 (en) * | 2019-05-20 | 2020-11-26 | Instituto De Biologia Experimental E Tecnologica (Ibet) | Modified envelope glycoproteins for retroviridae viral vector pseudotyping and process for obtaining it |
EP4086352A1 (en) | 2021-05-07 | 2022-11-09 | Medizinische Hochschule Hannover | Glycoproteins for pseudotyping retroviral vector particles |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4682195A (en) | 1985-09-30 | 1987-07-21 | General Electric Company | Insulated gate device with configured emitter contact pad |
EP0266032A1 (en) | 1986-08-29 | 1988-05-04 | Beecham Group Plc | Modified fibrinolytic enzyme |
US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
DE4204650C1 (zh) | 1992-02-15 | 1993-07-08 | Hoffmeister, Helmut, Dr., 4400 Muenster, De | |
DE4228457A1 (de) | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen |
US5834256A (en) | 1993-06-11 | 1998-11-10 | Cell Genesys, Inc. | Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells |
FR2722208B1 (fr) | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
US5705629A (en) | 1995-10-20 | 1998-01-06 | Hybridon, Inc. | Methods for H-phosphonate synthesis of mono- and oligonucleotides |
US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
GB9621680D0 (en) * | 1996-10-17 | 1996-12-11 | Oxford Biomedica Ltd | Lentiviral vectors |
US5846225A (en) | 1997-02-19 | 1998-12-08 | Cornell Research Foundation, Inc. | Gene transfer therapy delivery device and method |
CA2288328A1 (en) * | 1997-05-13 | 1998-11-19 | University Of North Carolina At Chapel Hill | Lentivirus-based gene transfer vectors |
US6136597A (en) | 1997-09-18 | 2000-10-24 | The Salk Institute For Biological Studies | RNA export element |
US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
US6849454B2 (en) * | 2000-03-07 | 2005-02-01 | St. Jude Children's Research Hospital | Highly efficient gene transfer into human repopulating stem cells by RD114 pseudotyped retroviral vector particles |
-
2003
- 2003-04-25 CN CNB038135329A patent/CN100340668C/zh not_active Expired - Fee Related
- 2003-04-25 EP EP03747185A patent/EP1499736B1/en not_active Expired - Lifetime
- 2003-04-25 AU AU2003226598A patent/AU2003226598A1/en not_active Abandoned
- 2003-04-25 KR KR1020047017296A patent/KR101002955B1/ko not_active IP Right Cessation
- 2003-04-25 WO PCT/IB2003/001597 patent/WO2003091442A1/en active Application Filing
- 2003-04-25 US US10/512,474 patent/US8338168B2/en not_active Expired - Fee Related
- 2003-04-25 DK DK03747185T patent/DK1499736T3/da active
- 2003-04-25 AT AT03747185T patent/ATE424464T1/de active
- 2003-04-25 JP JP2003587970A patent/JP4343708B2/ja not_active Expired - Fee Related
- 2003-04-25 ES ES03747185T patent/ES2326217T3/es not_active Expired - Lifetime
- 2003-04-25 CA CA2484166A patent/CA2484166C/en not_active Expired - Fee Related
- 2003-04-25 DE DE60326444T patent/DE60326444D1/de not_active Expired - Lifetime
-
2005
- 2005-07-22 HK HK05106240.0A patent/HK1073479A1/xx not_active IP Right Cessation
-
2012
- 2012-11-14 US US13/676,852 patent/US9090908B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DE60326444D1 (de) | 2009-04-16 |
CA2484166A1 (en) | 2003-11-06 |
US20140004089A1 (en) | 2014-01-02 |
US9090908B2 (en) | 2015-07-28 |
US8338168B2 (en) | 2012-12-25 |
JP2005523706A (ja) | 2005-08-11 |
AU2003226598A1 (en) | 2003-11-10 |
KR20050008697A (ko) | 2005-01-21 |
CN1659284A (zh) | 2005-08-24 |
WO2003091442A1 (en) | 2003-11-06 |
HK1073479A1 (en) | 2005-10-07 |
JP4343708B2 (ja) | 2009-10-14 |
ATE424464T1 (de) | 2009-03-15 |
EP1499736A1 (en) | 2005-01-26 |
US20060257366A1 (en) | 2006-11-16 |
KR101002955B1 (ko) | 2010-12-21 |
ES2326217T3 (es) | 2009-10-05 |
AU2003226598A8 (en) | 2003-11-10 |
CN100340668C (zh) | 2007-10-03 |
CA2484166C (en) | 2011-11-29 |
EP1499736B1 (en) | 2009-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1073479A1 (en) | Improved chimeric glycoproteins and pseudotyped lentiviral vectors | |
CA2442679A1 (en) | Methods for secretory production of proteins | |
AU2220800A (en) | Compositions and methods for packaging of alphavirus vectors | |
MY102902A (en) | Lymphokine production and purification. | |
DK0842279T3 (da) | Hjælpevirus til fremstilling af rekombinante virusvektorer | |
ATE454039T1 (de) | Verfharen zur herstellung von herpes-simplex- virus-amplikons, die resultierenden amplikons und ihre verwendung | |
ATE197608T1 (de) | Signalsequenzen für die secretion heterologer proteine von hefe | |
CA2498668A1 (en) | Generation of plants with improved drought tolerance | |
EP1029918A4 (en) | HIV-RECOGNIZING T-KILLER T-LYMPHOCYTE RECEPTOR | |
AU2003294397A8 (en) | Promoter variants for expressing genes in a fungal cell | |
DK1546302T3 (da) | Fremgangsmåder til fremstilling af pattedyrs-trypsiner | |
EP1262551A3 (en) | A sorbitol dehydrogenase gene, a recombinant DNA, and a process for producing sorbitol dehydrogenase | |
EP0475182A3 (en) | Method for protein synthesis using cks fusion proteins | |
KR102121817B1 (ko) | Crispr 편집 기술을 이용한 재조합 항원을 발현시키는 벡터 및 이를 동시에 다중 삽입시키는 방법 | |
EP1163844A4 (en) | TRANSGENIC MOLLUSK AND ITS CREATION METHOD | |
DE50109097D1 (de) | Promotoren zur genexpression in karyopsen von pflanzen | |
MX2023009213A (es) | Construccion y aplicacion de un mutante de la omega-transaminasa reversible enantioselectivamente. | |
CA2354844A1 (en) | Vectors having terminal repeat sequence of epstein-barr virus | |
NZ596925A (en) | Polymer particles and uses thereof | |
GR1005101B (el) | Ανασυνδυασμενες πρωτεϊνες με περιοχες προσδεσης λιπιδιων ως συμπληρωματα θρεπτικων υλικων ελευθερωνορρου για μεγιστοποιηση της επιμολυνσης κυτταροκαλλιεργειων απο πυρηνικους πολυεδρικους ιους (μπακουλοϊους), υψηλη παραγωγη μπακουλοϊων και υψηλη παραγωγη ανασυνδυασμενων πρωτεϊνων μεσω φορεων εκφρασης μπακουλοϊων: παρασκευη και μεθοδοι χρησης | |
DK0959130T3 (da) | Kloning og udtrykkelse af nyt glucoamylasegen fra Endomyces fibuliger |